| Barchart Demo Center |
$7,71
+0,05 (+0,65%)
en date du mai 31, 2024
en date du mai 31, 2024
| Dernière | 7,71 |
|---|---|
| Variation | +0,05 (+0,65%) |
| Ouverture | 7,75 |
| Clôture précédente | 7,66 |
| Écart (actuel) |
7,56
8,30
|
| Écart 52 semaines |
2,34
11,55
|
| Volume | 68 700 |
| Volume Moyen | 229 235 |
| Secteur | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Nom | Aujourd'hui | 3-mois | 1 an |
|---|---|---|---|
| ELYM |
 +0,65% |
 +176,34% |
+157,00% |
| DJIA |
+1,51% |
 -2,09% |
+16,90% |
| S&P 500 |
+0,80% |
+1,01% |
+25,49% |
Statistiques clef
| BPA Annuel | N/A |
|---|---|
| Rendement dividendes | 0,00% |
| Rapport Prix/Bénéfices | N/A |
| Market Capitalization, $K | 223 130 |
| Alpha pondéré | -11,74 |
| Écart-type | +0,09 |
| Marge d'exploitation | N/A |
| Beta | -0,36 |
Taux de croissance
| Cette année | +185,56% | |||
| 1 An(s) | +161,36% |
Opinion
| Vendre | Conserver | Acheter |
Articles récents
SHAREHOLDER ALERT: Kaskela Law LLC Announces
PR Newswire - Mon Apr 15, 07:15AM CDT
/PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders....(version intégrale)
ELYM: 7,71 (+0,05)
Kuehn Law Encourages ALPN, JBT, ELYM, and HRT
PR Newswire - Thu Apr 11, 03:27PM CDT
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...(version intégrale)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC
PR Newswire - Thu Apr 11, 12:02PM CDT
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...(version intégrale)
ELYM Stock Alert: Halper Sadeh LLC Is Investigating
Business Wire - Thu Apr 11, 07:30AM CDT
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shareholders.(version intégrale)
ELYM: 7,71 (+0,05)
Eliem Therapeutics Announces Agreement to Acquire
GlobeNewswire - Thu Apr 11, 06:00AM CDT
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have...(version intégrale)
ELYM: 7,71 (+0,05)